(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?

描述(申请人提供)：本申请是对RFA-CA12-022的回应。它解决了PQD-2，哪些分子特性使一些癌症可以用传统的化疗治愈？我们选择EBV+地方性Burkitt淋巴瘤(BL)作为典型的癌症，用单一药物(环磷酰胺)可以治愈90%的儿童。这种极高的治愈率在20世纪60年代在非常有限的环境中已经很明显(乌干达)，此后在美国、巴西和其他国家重复出现。失败是由于辅助因素，包括社会经济和总体表现评分，这些因素限制了患者完成规定的周期数，而不是分子异质性。因此，这种侵袭性很强的癌症可以治愈的原因是分子性质的。我们将使用功能遗传学方法来了解使BL对最简单的化疗之一敏感的分子特性。

DESCRIPTION (provided by applicant): This application is in response to RFA-CA12-022. It addresses PQD - 2 what molecular properties make some cancers curable with conventional chemotherapy? We choose EBV+ endemic Burkitt lymphoma (BL) as the prototypical cancer that is curable with single agent (cyclophosphamide) in >90% of children. This exceedingly high cure rate was already evident in the 1960s in very limited settings (Uganda) and has since been repeated in the US, in Brazil and other nations. Failure is due to co-factors, including socioeconomically and over all performance score, which limit the patients to complete the prescribed number of cycles, rather than molecular heterogeneity. Hence, the reason that this very aggressive cancer is curable is molecular in nature. We will use a functional genetic approach to understand the molecular properties that render BL susceptible to one of the simplest of chemotherapies.